A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
RF, Riedel⋅Riedel, Richard F⋅RF, Riedel⋅KV, Ballman⋅KV, Ballman⋅Ballman, Karla V⋅Attia, Steven⋅Y, Lu⋅Y, Lu⋅Loggers, Elizabeth T⋅S, Attia⋅S, Attia⋅ET, Loggers⋅Ganjoo, Kristen N⋅ET, Loggers⋅KN, Ganjoo⋅KN, Ganjoo⋅Livingston, Michael B⋅MB, Livingston⋅MB, Livingston⋅Chow, Warren⋅Wright, Jennifer⋅W, Chow⋅W, Chow⋅Ward, John H⋅J, Wright⋅J, Wright⋅Rushing, Daniel⋅JH, Ward⋅JH, Ward⋅D, Rushing⋅D, Rushing⋅Okuno, Scott H⋅SH, Okuno⋅SH, Okuno⋅Reed, Damon R⋅DR, Reed⋅DR, Reed⋅Liebner, David A⋅Keedy, Vicki L⋅DA, Liebner⋅DA, Liebner⋅RG, Maki⋅RG, Maki⋅Mascarenhas, Leo⋅Davis, Lara E⋅Ryan, Christopher⋅Reinke, Denise K and Maki, Robert G
The oncologist, July 23, 2020. | Journal Article